"Cysteine Endopeptidases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
ENDOPEPTIDASES which have a cysteine involved in the catalytic process. This group of enzymes is inactivated by CYSTEINE PROTEINASE INHIBITORS such as CYSTATINS and SULFHYDRYL REAGENTS.
| Descriptor ID |
D003546
|
| MeSH Number(s) |
D08.811.277.656.262.500 D08.811.277.656.300.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cysteine Endopeptidases".
Below are MeSH descriptors whose meaning is more specific than "Cysteine Endopeptidases".
This graph shows the total number of publications written about "Cysteine Endopeptidases" by people in this website by year, and whether "Cysteine Endopeptidases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 3 | 4 |
| 2004 | 3 | 3 | 6 |
| 2005 | 6 | 5 | 11 |
| 2006 | 8 | 3 | 11 |
| 2007 | 2 | 3 | 5 |
| 2008 | 3 | 1 | 4 |
| 2009 | 3 | 0 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 3 | 5 |
| 2016 | 1 | 0 | 1 |
| 2017 | 6 | 7 | 13 |
| 2018 | 10 | 6 | 16 |
| 2019 | 1 | 1 | 2 |
| 2020 | 8 | 14 | 22 |
| 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Cysteine Endopeptidases" by people in Profiles.
-
Enteroviruses and coronaviruses: similarities and therapeutic targets. Expert Opin Ther Targets. 2021 06; 25(6):479-489.
-
Self-Masked Aldehyde Inhibitors: A Novel Strategy for Inhibiting Cysteine Proteases. J Med Chem. 2021 08 12; 64(15):11267-11287.
-
Structure-Based Discovery of Novel Nonpeptide Inhibitors Targeting SARS-CoV-2 Mpro. J Chem Inf Model. 2021 08 23; 61(8):3917-3926.
-
Efficiency Improvements and Discovery of New Substrates for a SARS-CoV-2 Main Protease FRET Assay. SLAS Discov. 2021 10; 26(9):1189-1199.
-
The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CLpro In Vitro. Viruses. 2021 05 10; 13(5).
-
Inhibition mechanism and hot-spot prediction of nine potential drugs for SARS-CoV-2 Mpro by large-scale molecular dynamic simulations combined with accurate binding free energy calculations. Nanoscale. 2021 May 07; 13(17):8313-8332.
-
[Optimization of expression conditions and determination the proteolytic activity of codon-optimized SARS-CoV-2 main protease in Escherichia coli]. Sheng Wu Gong Cheng Xue Bao. 2021 Apr 25; 37(4):1334-1345.
-
Mass spectrometry reveals potential of ß-lactams as SARS-CoV-2 Mpro inhibitors. Chem Commun (Camb). 2021 Feb 15; 57(12):1430-1433.
-
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking. J Nanosci Nanotechnol. 2020 12 01; 20(12):7311-7323.
-
Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. Nat Commun. 2020 11 18; 11(1):5877.